A Phase I, Open-label, Single-dose, Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of the UB-421 Antibody in Asymptomatic HIV-1 Infected Adults.
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2011
At a glance
- Drugs UB 421 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 08 Jul 2011 Actual end date (Jul 2011) added as reported by ClinicalTrials.gov.
- 08 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.